Stockscreener 앱 받기
16.38
4.63%
-0.795
시간 외 거래:
16.68
0.30
+1.83%
전일 마감가:
$17.18
열려 있는:
$17.5
하루 거래량:
2.83M
Relative Volume:
0.68
시가총액:
$1.16B
수익:
-
순이익/손실:
$-117.81M
주가수익비율:
-8.7128
EPS:
-1.88
순현금흐름:
$74.30M
1주 성능:
+4.26%
1개월 성능:
+73.70%
6개월 성능:
+430.10%
1년 성능:
+66.46%
1일 변동 폭
$16.29
$17.63
1주일 범위
$14.43
$17.63
52주 변동 폭
$2.95
$17.65
Omeros Corporation Stock (OMER) Company Profile
명칭
Omeros Corporation
전화
206-676-5000
주소
201 ELLIOTT AVENUE WEST, SEATTLE, WA
OMER을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
16.38 | 1.22B | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-10 | 개시 | H.C. Wainwright | Buy |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
| 2022-12-08 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-11-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-06-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-10-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2021-10-01 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-09-27 | 개시 | JP Morgan | Neutral |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-08-21 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2019-05-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-12 | 개시 | Seaport Global Securities | Buy |
| 2018-03-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-03-05 | 다운그레이드 | Needham | Buy → Hold |
| 2017-11-08 | 개시 | H.C. Wainwright | Buy |
| 2017-05-11 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | 재확인 | Maxim Group | Buy |
| 2017-03-17 | 재확인 | Needham | Buy |
| 2016-11-16 | 재확인 | Wedbush | Outperform |
| 2016-11-10 | 재확인 | Needham | Buy |
| 2016-08-10 | 재확인 | Maxim Group | Buy |
| 2016-06-03 | 개시 | Cantor Fitzgerald | Buy |
| 2016-03-02 | 재확인 | Needham | Buy |
| 2016-02-29 | 재확인 | Wedbush | Outperform |
| 2015-11-11 | 재확인 | Needham | Buy |
| 2015-08-18 | 재확인 | WBB Securities | Strong Buy |
| 2015-08-10 | 개시 | ROTH Capital | Buy |
모두보기
Omeros Corporation 주식(OMER)의 최신 뉴스
Omeros (NASDAQ:OMER) Sets New 12-Month HighStill a Buy? - MarketBeat
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside - MSN
Will Omeros Corporation stock deliver better than expected guidanceGrowth Stock Opportunities & Ride the Wave of Market-Beating Growth - bollywoodhelpline.com
Omeros (NASDAQ:OMER) Trading Up 4.6%Here's Why - MarketBeat
Retail’s Christmas Eve watchlist: Omeros, Nike, Citi, Dynavax and Agios spark most market chatter - MSN
Commit To Buy Omeros At $10, Earn 26.6% Annualized Using Options - Nasdaq
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA - Yahoo Finance
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - MSN
Omeros Corp Announces FDA Approval of YARTEMLEA for TA-TMA - TradingView — Track All Markets
Omeros (NASDAQ: OMER) secures FDA nod for YARTEMLEA in TA-TMA - Stock Titan
Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade) - Seeking Alpha
Omeros to resume trading at 9:50 AM ET - MSN
D Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains buy rating - MSN
Why Omeros stock skyrocketed today - MSN
Omeros Announces New Date for YARTEMLEA® Approval Conference Call - Caledonian Record
Omeros scores its 1st FDA nod as stem cell transplant drug Yartemlea approved - Fierce Pharma
Omeros (NASDAQ:OMER) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Omeros rockets as FDA approves Yartemlea - The Pharma Letter
Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER) - The Globe and Mail
WBB Securities Reaffirms Their Buy Rating on Omeros (OMER) - The Globe and Mail
Omeros (OMER): Revisiting Valuation After a Powerful Multi‑Year Share Price Repricing - Yahoo Finance
Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook - ts2.tech
Omeros wins FDA nod for transplant therapy - MSN
Omeros (NASDAQ:OMER) Hits New 12-Month HighTime to Buy? - MarketBeat
Omeros (OMER) Valuation After FDA Approval of First TA-TMA Therapy Yartemlea and Shift to Commercial Stage - simplywall.st
Corient Private Wealth LLC Reduces Stock Holdings in Omeros Corporation $OMER - MarketBeat
Why Omeros (OMER) Is Up 74.0% After First-In-Class TA-TMA Drug Wins FDA Approval - Yahoo Finance
Nike, Omeros Corporation, Micron Technology, Intel And Dynavax Technologies: Why These 5 Stocks Are On Investors' Radars Today - Sahm
NKE, OMER, MU, INTC, DVAX: 5 Trending Stocks TodayNike (NYSE:NKE) - Benzinga
Omeros Stock Jumps Premarket After FDA Approves First Drug For Rare Transplant Complication — Retail Sees Big Upside - Stocktwits
Why Omeros Stock Skyrocketed Today - AOL.com
Why Omeros Stock Skyrocketed Today - The Motley Fool
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open - ts2.tech
US FDA approves Omeros' drug to treat dangerous transplant complication - Reuters
Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter - Asianet Newsable
Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely (NASDAQ:OMER) - Seeking Alpha
FDA approves Omeros’ Yartemlea for stem cell patients - BioWorld MedTech
Omeros' Yartemlea lands FDA nod for often-fatal transplant complication - FirstWord Pharma
Stock Traders Buy High Volume of Call Options on Omeros (NASDAQ:OMER) - MarketBeat
Omeros' (OMER) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
OMER: Analyst Maintains 'Buy' Rating and $36 Price Target | OMER Stock News - GuruFocus
H.C. Wainwright Maintains Omeros(OMER.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
Omeros (NASDAQ:OMER) Trading Up 74.2%What's Next? - MarketBeat
Omeros (OMER) Secures FDA Approval for Breakthrough Treatment - GuruFocus
Why Is Omeros Stock Skyrocketing Wednesday?Omeros (NASDAQ:OMER) - Benzinga
Omeros stock garners high retail attention ahead of FDA verdict for life-saving drug - MSN
Omeros (OMER) Gains Buy Rating After FDA Approval of Yartemlea - GuruFocus
Omeros (OMER) Set to Resume Trading After FDA Approval News - GuruFocus
Omeros stock soars after FDA approves first treatment for TA-TMA By Investing.com - Investing.com Australia
Omeros Corporation (OMER) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):